JP2014503537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503537A5 JP2014503537A5 JP2013545218A JP2013545218A JP2014503537A5 JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5 JP 2013545218 A JP2013545218 A JP 2013545218A JP 2013545218 A JP2013545218 A JP 2013545218A JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- breast cancer
- positive
- treatment
- body according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10196960.8 | 2010-12-24 | ||
| EP10196960 | 2010-12-24 | ||
| PCT/EP2011/073041 WO2012084711A1 (en) | 2010-12-24 | 2011-12-16 | N-substituted azetidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503537A JP2014503537A (ja) | 2014-02-13 |
| JP2014503537A5 true JP2014503537A5 (enExample) | 2014-08-21 |
| JP5886873B2 JP5886873B2 (ja) | 2016-03-16 |
Family
ID=43778253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013545218A Expired - Fee Related JP5886873B2 (ja) | 2010-12-24 | 2011-12-16 | Ｎ置換アゼチジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9540361B2 (enExample) |
| EP (1) | EP2655367B1 (enExample) |
| JP (1) | JP5886873B2 (enExample) |
| AU (1) | AU2011347718B2 (enExample) |
| CA (1) | CA2819299A1 (enExample) |
| ES (1) | ES2586908T3 (enExample) |
| WO (1) | WO2012084711A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012014431A (es) | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | Modulares del receptor de estrogenos y usos de los mismos. |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| MX357496B (es) | 2011-12-14 | 2018-07-11 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrógenos fluorados y sus usos. |
| DK2958907T3 (en) | 2013-02-19 | 2018-06-06 | Novartis Ag | Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders |
| NZ769496A (en) | 2014-12-18 | 2023-09-29 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) * | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| IL310489A (en) | 2015-10-01 | 2024-03-01 | Olema Pharmaceuticals Inc | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS AND COMPOSITIONS COMPRISING SAME FOR USE IN TREATING CANCER |
| EP3374356A1 (en) * | 2015-11-09 | 2018-09-19 | H. Hoffnabb-La Roche Ag | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
| HRP20221462T1 (hr) | 2015-12-09 | 2023-01-20 | The Board Of Trustees Of The University Of Illinois | Selektivni nishodni regulatori receptora estrogena na bazi benzotiofena |
| PE20181893A1 (es) * | 2016-02-15 | 2018-12-11 | Sanofi Sa | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos |
| US9969732B2 (en) * | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| KR20190025943A (ko) | 2016-07-01 | 2019-03-12 | 쥐원 쎄라퓨틱스, 인크. | 피리미딘-기재 항증식제 |
| PT3433256T (pt) * | 2016-10-24 | 2019-10-31 | Astrazeneca | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento do cancro |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| JP6946430B2 (ja) | 2016-11-17 | 2021-10-06 | サノフイＳａｎｏｆｉ | 新規の置換ｎ−（３−フルオロプロピル）−ピロリジン化合物、それを製造するための方法、およびその治療的使用 |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| WO2018138739A1 (en) | 2017-01-27 | 2018-08-02 | Sun Pharma Advanced Research Company Limited | Novel antiestrogenic heterocyclic compounds |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| CN112041307B (zh) * | 2018-02-06 | 2024-02-09 | 伊利诺伊大学评议会 | 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物 |
| KR102564647B1 (ko) | 2018-06-21 | 2023-08-11 | 에프. 호프만-라 로슈 아게 | 3-((1R,3R)-1-(2,6-다이플루오로-4-((1-(3-플루오로프로필)아제티딘-3-일)아미노)페닐)-3-메틸-1,3,4,9-테트라하이드로-2H-피리도[3,4-b]인돌-2-일)-2,2-다이플루오로프로판-1-올의 고체 형태, 치환된 페닐 또는 피리딘일 잔기를 포함하는 융합된 삼환형 화합물의 제조 방법, 및 이의 사용 방법 |
| AU2019335542A1 (en) | 2018-09-07 | 2021-04-01 | Sanofi | Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-(4-((3s)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxyphenyl)-8,9-dihydro-7H-benzo(7)annulene-2-carboxylate |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| MX2022000279A (es) | 2019-07-07 | 2022-02-03 | Olema Pharmaceuticals Inc | Regimenes de antagonistas del receptor de estrogeno. |
| MX2022007659A (es) | 2019-12-20 | 2022-07-19 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr). |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| CN115175679A (zh) | 2020-03-06 | 2022-10-11 | 奥列马制药公司 | 治疗雌激素受体相关疾病的方法 |
| JP2023538517A (ja) | 2020-08-05 | 2023-09-08 | シーフォー セラピューティクス， インコーポレイテッド | Ｒｅｔの標的分解のための化合物 |
| CN113248455A (zh) * | 2021-05-25 | 2021-08-13 | 湖北科技学院 | 一种3,5-二取代异噁唑类衍生物及其合成方法 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| WO2023059714A1 (en) * | 2021-10-06 | 2023-04-13 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| JP2025525917A (ja) | 2022-08-03 | 2025-08-07 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｅｔタンパク質を調節するための化合物 |
| CN117924262A (zh) * | 2022-10-14 | 2024-04-26 | 中国科学院上海药物研究所 | 二氢苯并噻喃类衍生物及其制备方法和用途 |
| EP4611900A1 (en) | 2022-11-04 | 2025-09-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
| CN120569388A (zh) | 2022-11-04 | 2025-08-29 | 百时美施贵宝公司 | Ret-ldd蛋白降解剂 |
| CN116813603B (zh) * | 2023-06-02 | 2024-10-22 | 成都市第三人民医院 | 一种选择性雌激素受体α降解化合物及其制备方法和应用 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983245A (en) * | 1975-02-06 | 1976-09-28 | Smithkline Corporation | Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes |
| US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| DOP2002000467A (es) * | 2001-10-10 | 2003-04-15 | Pfizer Prod Inc | 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas |
| TW200304371A (en) * | 2002-02-22 | 2003-10-01 | Akzo Nobel Nv | Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors |
| US20030225132A1 (en) | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| SI1501819T1 (sl) | 2002-04-24 | 2011-01-31 | Merck Sharp & Dohme | Modulatorji estrogen receptorjev |
| WO2004058682A1 (ja) * | 2002-12-26 | 2004-07-15 | Eisai Co., Ltd. | 選択的エストロゲン受容体モジュレーター |
| EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
-
2011
- 2011-12-16 ES ES11794797.8T patent/ES2586908T3/es active Active
- 2011-12-16 US US13/995,237 patent/US9540361B2/en active Active
- 2011-12-16 EP EP11794797.8A patent/EP2655367B1/en active Active
- 2011-12-16 CA CA2819299A patent/CA2819299A1/en not_active Abandoned
- 2011-12-16 WO PCT/EP2011/073041 patent/WO2012084711A1/en not_active Ceased
- 2011-12-16 AU AU2011347718A patent/AU2011347718B2/en not_active Ceased
- 2011-12-16 JP JP2013545218A patent/JP5886873B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503537A5 (enExample) | ||
| CL2015002098A1 (es) | “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct | |
| GT201500206A (es) | Modulador del receptor de andrógeno y usos de este | |
| MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
| MX2015011579A (es) | Terapia de combinacion para el tratamiento de la neoplasia. | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| ZA201007529B (en) | Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterinefibroids, dysmenorrhea,breast cancer etc | |
| MX359639B (es) | Metodos y composiciones para uso en tratamientos celulares. | |
| SG11201704660YA (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| NZ756730A (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
| MX345788B (es) | Nuevo tratamiento del carcinoma de prostata. | |
| SG11201603462SA (en) | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction | |
| WO2015104373A3 (en) | Duocarmycin adcs for use in treatment of endometrial cancer | |
| NI201200071A (es) | Nuevo uso antitumoral de cabazitaxel | |
| MX2015001716A (es) | Niclosamida para el tratamiento de tumores solidos. | |
| EA201890598A2 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
| IN2015MN00001A (enExample) | ||
| IL263562A (en) | Methods and compositions for prostate cancer diagnosis and treatment | |
| WO2014152451A3 (en) | Compositions and methods for controlled localized delivery of bone forming therapeutic agents | |
| PH12012501812A1 (en) | Compositions and methods for non-toxic delivery of antiprogestins | |
| IN2012DE00138A (enExample) | ||
| Boisen et al. | Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges | |
| SG11202000881VA (en) | Adjuvant therapy for use in prostate cancer treatment | |
| MX2019011118A (es) | Uso de oleorresina de copaifera en patologias de la prostata. | |
| NZ742470A (en) | Combination therapy for cancer |